Hyperparathyroidism - Pipeline Insight, 2025

This “Hyperparathyroidism - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hyperparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Hyperparathyroidism: Understanding

Hyperparathyroidism: Overview

Hyperparathyroidism occurs when one or more of the parathyroid glands become overactive and produce excessive amounts of parathyroid hormone (PTH). These small glands, located behind the thyroid at the base of the neck, are responsible for regulating calcium and phosphate levels in the blood. Normally, PTH signals the bones to release calcium and phosphate, the kidneys to reabsorb calcium while excreting phosphate, and the intestines to absorb calcium through activated vitamin D. However, in hyperparathyroidism, the overproduction of PTH leads to increased calcium levels (hypercalcemia) in the blood, which can cause bones to become thin and brittle, while also contributing to calcium buildup in the kidneys, blood vessels, and other tissues. This imbalance can result in a range of health issues, including kidney stones, cardiovascular problems, and weakened bones.

Primary hyperparathyroidism is often detected incidentally through routine blood tests, as many individuals may not exhibit symptoms initially. When symptoms do occur, they are typically the result of complications caused by elevated calcium levels in the blood and urine or reduced calcium in the bones. These symptoms can vary widely, ranging from mild and nonspecific to more severe. Common manifestations include weakened bones that are prone to fractures (osteoporosis), kidney stones, excessive urination, abdominal pain, fatigue, muscle weakness, depression, and memory issues. Other symptoms may include joint pain, nausea, vomiting, loss of appetite, constipation, confusion, and increased thirst. In some cases, individuals may not experience noticeable symptoms and may only be diagnosed through blood tests conducted for other reasons.

Hyperparathyroidism is caused by factors that lead to an overproduction of parathyroid hormone (PTH), which can occur due to primary, secondary, or tertiary conditions. In primary hyperparathyroidism, the overproduction of PTH is often due to a benign growth (adenoma) on one or more of the parathyroid glands or enlargement (hyperplasia) of the glands, with a rare cause being parathyroid cancer. Secondary hyperparathyroidism is typically the result of an underlying condition such as severe calcium deficiency, vitamin D deficiency, or chronic kidney failure, where the parathyroid glands overcompensate to restore calcium levels. In cases of chronic kidney disease, the kidneys’ reduced ability to convert vitamin D leads to low calcium levels, prompting increased PTH production. If secondary hyperparathyroidism persists, it can progress to tertiary hyperparathyroidism, where the parathyroid glands become enlarged and function independently, producing excessive PTH even without the usual regulatory signals.

Hyperparathyroidism is often first detected through routine blood tests revealing elevated calcium levels, prompting further evaluation. Confirmatory blood tests for high parathyroid hormone (PTH) levels are crucial for diagnosis, and additional tests, such as bone mineral density scans, urine tests, and imaging of the kidneys, may be conducted to assess potential complications and severity. Treatment options for primary hyperparathyroidism typically include surgery, which is the most effective approach, especially if one or more glands are overactive. In cases where surgery is not feasible, medications such as calcimimetics or vitamin D analogs may be prescribed. Watchful waiting may also be recommended for individuals with mild symptoms and stable calcium levels. Although surgery offers a high rate of success, potential risks include nerve damage and long-term calcium imbalances, which may require ongoing supplementation. Medications can help manage secondary hyperparathyroidism, particularly in cases related to chronic kidney disease, and hormone replacement therapy or bisphosphonates may be used to address bone density loss, although they do not treat the underlying parathyroid issue.

'Hyperparathyroidism- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperparathyroidism pipeline landscape is provided which includes the disease overview and Hyperparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hyperparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperparathyroidism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hyperparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve Hyperparathyroidism.

Hyperparathyroidism Emerging Drugs Chapters

This segment of the Hyperparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperparathyroidism Emerging Drugs

SHR6508: Shanghai Hengrui Pharmaceutical Co., Ltd.

SHR6508 is a novel calcimimetic small molecule drug developed by Shanghai Hengrui Pharmaceutical Co., Ltd. targeting secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease undergoing hemodialysis. As a calcium-sensing receptor agonist, the drug works by modulating calcium signaling pathways in parathyroid cells, which helps suppress excessive parathyroid hormone (PTH) production. While the precise molecular mechanism remains under investigation, SHR6508 represents an innovative therapeutic approach in the management of secondary hyperparathyroidism, focusing on directly influencing calcium-sensing receptor activity to restore hormonal balance. Currently, the drug is in Phase III stage of its development for the treatment of Hyperparathyroidism.

MT1013: Shaanxi Micot Technology Limited Company

MT1013 is an innovative investigational therapeutic candidate developed by Shaanxi Micot Technology Limited Company specifically targeting secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease. As a PTH1R antagonist, the drug is designed to modulate parathyroid hormone receptor signaling, potentially offering a novel approach to managing abnormal parathyroid hormone levels. The medication's mechanism of action focuses on interrupting the calcium-mediated signaling pathways in parathyroid cells, which could help reduce excessive parathyroid hormone production commonly observed in patients with kidney dysfunction. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hyperparathyroidism.

Hyperparathyroidism: Therapeutic Assessment

This segment of the report provides insights about the different Hyperparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperparathyroidism

• There are approx. 3+ key companies which are developing the therapies for Hyperparathyroidism. The companies which have their Hyperparathyroidism drug candidates in the most advanced stage, i.e. Phase III include, Shanghai Hengrui Pharmaceutical Co., Ltd.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hyperparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperparathyroidism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hyperparathyroidism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperparathyroidism drugs.

Hyperparathyroidism Report Insights

• Hyperparathyroidism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperparathyroidism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperparathyroidism drugs?
• How many Hyperparathyroidism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperparathyroidism?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperparathyroidism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperparathyroidism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shanghai Hengrui Pharmaceutical Co., Ltd.

Shaanxi Micot Technology Limited Company

• Crinetics Pharmaceuticals, Inc.

Pathalys Pharma

Key Products

• SHR6508
• MT1013
• PTH Antagonist
• PLS240

This product will be delivered within 2 business days.